Johnson & Johnson (JNJ) stock
Close on Nov 13, 2026Market cap $687.89BP/E 43.4Yield 1.80%
Johnson & Johnson grew revenue 7.8% to $99.34B over the twelve months to Sep 27, 2026. Free cash flow was $20.59B, up 5.1% from a year earlier. At the latest close the market valued the company at $687.89B, 43.4 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 27, 2026
Valuation
- Market cap
- $687.89B
- P/E ratio
- 43.4
- Price to sales
- 6.92
- Price to book
- 8.44
- Dividend yield
- 1.80%
- Free cash flow yield
- 2.99%
Fundamentals
- Revenue
- $99.34B
- Net income
- $16.10B
- EPS, diluted
- $6.59
- Free cash flow
- $20.59B
- Book value per share
- $33.30
- Diluted shares
- 2.45B
Trading
- Next earnings
- Jan 20, 2027 (estimated, before the open)
- Previous close
- $283.52
- Open
- $285.00
- Day's range
- $281.68 – $288.11
- Volume
- 6,291,244
- Average volume (20 days)
- 7,459,857
- Index membership
- S&P 500, Dow Jones Industrial Average, Russell 1000, Russell 3000
- Beta (5 years)
- 0.20
- 52-week range
- $193.45 – $288.11
- RSI (14 days)
- 65.6
- Volatility (1 year)
- 21.1%
- Relative volume
- 0.87×
- WACC
- 7.4%
On 1 of our idea list: Superinvestor favorites
Index membership is inferred from the holdings of funds that track each index (VOO, IVV, SPYM, UDOW, DDM, IWB, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2009, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | JNJ | S&P 500 | Difference | JNJ per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +14.9% | -3.0% | +18.0 pts | ||
| 3 months | +9.6% | -2.8% | +12.4 pts | ||
| Year to date | +40.3% | +11.5% | +28.8 pts | ||
| 1 year | +49.6% | +13.5% | +36.2 pts | ||
| 3 years | +110.8% | +77.7% | +33.1 pts | +28.2% | +21.1% |
| 5 years | +99.1% | +72.6% | +26.5 pts | +14.8% | +11.5% |
| 10 years | +216.6% | +308.2% | −91.6 pts | +12.2% | +15.1% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Johnson & Johnson filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Update
- Update
- Update
- Results
About Johnson & Johnson
Pharmaceutical Preparations
Johnson & Johnson is a healthcare holding company that researches, develops, and manufactures products focused on human health and well-being. The company operates through two main business segments: Innovative Medicine and MedTech. Its Innovative Medicine division focuses on therapeutic areas including oncology, immunology, neuroscience, infectious diseases, cardiovascular and metabolism, and pulmonary hypertension. Its MedTech segment provides products and technologies for cardiovascular care, orthopaedics, surgery, and vision care. Products are distributed to retailers, wholesalers, hospitals, clinics, and healthcare professionals for patient and surgical use.
Company profile, executives and historyJohnson & Johnson stock: common questions
What is Johnson & Johnson's stock price?
JNJ closed at $285.75 on Nov 13, 2026, up 0.79% on the day. Over the past 52 weeks it traded between $193.45 and $288.11.
What is Johnson & Johnson's market cap?
Johnson & Johnson was worth $687.89B at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is JNJ's P/E ratio?
JNJ trades at 43.4 times earnings, based on diluted earnings per share of $6.59 over the twelve months to Sep 27, 2026.
How much revenue does Johnson & Johnson make?
Johnson & Johnson reported revenue of $99.34B for the twelve months to Sep 27, 2026, up 7.8% from a year earlier.
Does Johnson & Johnson pay a dividend?
Yes. Johnson & Johnson paid $5.14 per share over the last twelve months, a yield of 1.80% at the latest price, and has raised its annual dividend 18 years in a row.
When does Johnson & Johnson report earnings next?
Johnson & Johnson is expected to report Q4 FY2026 results on Jan 20, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has JNJ stock performed over the past year?
Including dividends, JNJ returned +49.6% over the past year, against +13.5% for the S&P 500.
How many JNJ shares are sold short?
17M shares were sold short at the latest FINRA report, 0.71% of the float, or 2.4 days of average trading volume.
Who are Johnson & Johnson's competitors?
Companies most similar to Johnson & Johnson by business, industry and size include MRK, LLY, ABT, ABBV, PFE.
See a number that looks wrong?